Supplemental Table 1. Characteristics of infused T cells.

Phenotype of the CD3^+CD19^+ cell lines prior to infusion for pts. 1-12, according to lymphocyte markers and memory markers; the latter is subdivided according to: central-memory (CD45RA^−CCR7^+), effector-memory (CD45RA^−CCR7^−) and effector-memory terminally differentiated phenotype (CD45RA^+CCR7^−).

Supplemental Figure 1. The kinetics of T-cell subsets after iC9-T cell infusion in each patient not treated with AP1903.

Counts of T-cell subsets in 8 patients who did not receive AP1903. (A) CD3^+CD19^+ T cells and (B) CD3^-CD19^- T cells. T lymphocytes subdivided according to CD3^+, CD4^+ and CD8^+ subtypes. (C) The copy number of the iC9 transgene per mg of DNA extracted from PBMC, evaluated by Q-PCR. Absolute count of CD3^-CD19^- T cells at the time of iC9-T cells infusion is: 5/µL (Pt. #1), 4/µL (Pt. #2), 5/µL (Pt. #3), 1/µL (Pt. #4), 24/µL (Pt. #5), 106/µL (Pt. #7), 4/µL (Pt. #10), 5/µL (Pt. #11).

Supplemental Figure 2. The kinetics of iC9-T cells, endogenous T cells and viral load in patients not treated with AP1903.

Viral load at multiple time points for each patient who did not receive AP1903. Pts. #5 (A) and #7 (B) had EBV reactivations; pt. #12 had CMV reactivation (C), and pt. #11 had HHV6 reactivation (D) before iC9-T cell infusion. Red line represents CD19^+T cells, blue line represents the CD19^- T cells, and green line indicates the viral load at multiple time points.
Supplementary Table 1.

<table>
<thead>
<tr>
<th>Pt.</th>
<th>CD3+</th>
<th>CD3+CD19+</th>
<th>CD4+CD19+</th>
<th>CD8+CD19+</th>
<th>CD3-CD56-CD16+</th>
<th>CD45RA-CCR7+</th>
<th>CD45RA-CCR7-</th>
<th>CD45RA+CCR7-</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>97</td>
<td>92</td>
<td>35</td>
<td>58</td>
<td>0.17</td>
<td>22.5</td>
<td>73.5</td>
<td>2.8</td>
</tr>
<tr>
<td>#2</td>
<td>98</td>
<td>96</td>
<td>31</td>
<td>62</td>
<td>0.47</td>
<td>11.7</td>
<td>85.9</td>
<td>2.0</td>
</tr>
<tr>
<td>#3</td>
<td>98</td>
<td>96</td>
<td>25</td>
<td>62</td>
<td>0.15</td>
<td>16.4</td>
<td>80.9</td>
<td>1.7</td>
</tr>
<tr>
<td>#4</td>
<td>98</td>
<td>94</td>
<td>36</td>
<td>50</td>
<td>0.01</td>
<td>28</td>
<td>64</td>
<td>4.5</td>
</tr>
<tr>
<td>#5</td>
<td>99</td>
<td>97</td>
<td>39</td>
<td>48</td>
<td>0.09</td>
<td>14.6</td>
<td>84.5</td>
<td>0.7</td>
</tr>
<tr>
<td>#6</td>
<td>98</td>
<td>96</td>
<td>43</td>
<td>51</td>
<td>0.02</td>
<td>53.1</td>
<td>46.3</td>
<td>0.4</td>
</tr>
<tr>
<td>#7</td>
<td>99</td>
<td>98</td>
<td>32</td>
<td>59</td>
<td>0.15</td>
<td>5.0</td>
<td>93.8</td>
<td>1.0</td>
</tr>
<tr>
<td>#8</td>
<td>99</td>
<td>98</td>
<td>31</td>
<td>60</td>
<td>0.04</td>
<td>37.2</td>
<td>62.2</td>
<td>0.4</td>
</tr>
<tr>
<td>#9</td>
<td>99</td>
<td>97</td>
<td>16</td>
<td>78</td>
<td>0.02</td>
<td>2.6</td>
<td>95.9</td>
<td>1.3</td>
</tr>
<tr>
<td>#10</td>
<td>96</td>
<td>94</td>
<td>23</td>
<td>68</td>
<td>0.19</td>
<td>26.4</td>
<td>73.1</td>
<td>0.4</td>
</tr>
<tr>
<td>#11</td>
<td>99</td>
<td>98</td>
<td>40</td>
<td>48</td>
<td>0.10</td>
<td>39.8</td>
<td>58.7</td>
<td>1.4</td>
</tr>
<tr>
<td>#12</td>
<td>97</td>
<td>93</td>
<td>45</td>
<td>45</td>
<td>0.03</td>
<td>0.6</td>
<td>95.2</td>
<td>4.1</td>
</tr>
</tbody>
</table>
Supplementary Figure 1.

A. CD3+CD19+ T cells

B. CD3+CD19- T cells

C. iC9 transgene copies / µg DNA

Months after T-cell infusion
Supplementary Figure 2.

A. EBV

Counts / µL

Months after T cells infusion

EBV Copies/µg of DNA

Pt. #5

CD3+19+

CD3+19-

EBV (copies)

B. EBV

Counts / µL

Months after T-cell infusion

EBV copies/µg of DNA

Pt. #7

CD3+19+

CD3+19-

EBV (copies)

C. CMV

Counts / µL

Weeks after T-cell infusion

CMV Copies/mL

Pt. #12

CD3+19+

CD3+19-

CMV (copies)

D. HHV6

Counts / µL

Months after T-cell infusion

HHV6 Copies/mL

Pt. #11

CD3+19+

CD3+19-

HHV6 (copies)